Pharmacies

• FDA announced new enforcement actions targeting compounding pharmacies producing GLP-1 drugs like semaglutide amid safety concerns. • The crackdown addresses risks from unapproved versions of weight-loss and diabetes medications flooding the market. • This policy shift aims to protect patients from potential contamination and dosing errors in the booming $100 billion GLP-1 sector.

• The FDA issued an urgent safety alert on March 20, 2026, warning of counterfeit versions of semaglutide and tirzepatide circulating through unverified online retailers, with 47 adverse events reported including severe infections and allergic reactions. • Counterfeit products lack sterility assurance and may contain contaminated ingredients or incorrect dosing, posing serious health risks to consumers seeking weight loss or diabetes treatment. • The agency recommends patients obtain GLP-1 medications only through licensed pharmacies with valid prescriptions, emphasizing that legitimate suppliers require medical supervision.

As outbreak in Kent claims the lives of two young people, experts advise against rushing to get a vaccinePharmacies in England are reporting a surge in demand for meningitis vaccines after an outbreak in Kent claimed the lives of two young people and left others in hospital.However experts have advised against rushing to get a jab, stressing public health authorities are best placed to determine if vaccinations are required – and for whom. Continue reading...